GAMMA Investing LLC Has $68,000 Holdings in Qiagen (NYSE:QGEN)

GAMMA Investing LLC increased its position in shares of Qiagen (NYSE:QGEN) by 170.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,518 shares of the company’s stock after buying an additional 956 shares during the period. GAMMA Investing LLC’s holdings in Qiagen were worth $68,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Toronto Dominion Bank acquired a new position in shares of Qiagen in the second quarter valued at $27,000. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after buying an additional 243 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Qiagen during the 3rd quarter worth about $53,000. Headlands Technologies LLC grew its stake in Qiagen by 396.6% in the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after buying an additional 2,189 shares during the last quarter. Finally, CWM LLC raised its holdings in Qiagen by 11.5% in the 3rd quarter. CWM LLC now owns 2,792 shares of the company’s stock valued at $127,000 after acquiring an additional 287 shares during the period. 70.00% of the stock is owned by institutional investors.

Analyst Ratings Changes

QGEN has been the subject of a number of research analyst reports. Hsbc Global Res upgraded Qiagen to a “hold” rating in a report on Thursday, October 17th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $48.00 price objective (down from $50.00) on shares of Qiagen in a report on Monday, January 6th. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a report on Thursday, October 17th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $54.00 price target (up from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Qiagen presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.50.

Qiagen Trading Down 1.2 %

Shares of QGEN stock opened at $44.70 on Monday. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.44. The stock’s fifty day moving average price is $44.03 and its two-hundred day moving average price is $43.92. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The company has a market cap of $10.20 billion, a PE ratio of 114.62, a P/E/G ratio of 3.52 and a beta of 0.37.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.